Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.

Autor: Kähler KC; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany. kckaehler@yahoo.de., Gutzmer R; Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum Medical School, Bochum, Germany., Angela Y; Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum Medical School, Bochum, Germany., Livingstone E; Department of Dermatology, University Hospital Essen, Essen, Germany., Lodde G; Department of Dermatology, University Hospital Essen, Essen, Germany., Meiss F; Department of Dermatology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany., Rafei-Shamsabadi DA; Department of Dermatology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany., Weyer-Fahlbusch SS; Department of Dermatology, Dortmund, Germany., Nashan D; Department of Dermatology, Dortmund, Germany., Loquai C; Department of Dermatology, Klinikum Bremen-Ost, Gesundheitnord gGmbH, Bremen, Germany., Hassel JC; Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germany., Sachse MMM; Department of Dermatology, Bremerhaven, Germany., Maul LV; Department of Dermatology, University Hospital Basel, Basel, Switzerland.; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland., Heinzerling L; Department of Dermatology and Allergy, University Hospital, LMU Munich, Munich, Germany., Heppt MV; Department of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander University (FAU) Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-European Metropolitan Area of Nuremberg (CCC ER-EMN), Erlangen, Germany., Colapietro C; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany., Rusch J; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Blome C; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2024 May 14; Vol. 150 (5), pp. 252. Date of Electronic Publication: 2024 May 14.

Phosphoinositide acyl chain saturation drives CD8 ⁺ effector T cell signaling and function.

Autor: Edwards-Hicks J; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Apostolova P; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Buescher JM; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Maib H; Division of Cell & Developmental Biology, School of Life Sciences, University of Dundee, Dundee, UK., Stanczak MA; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Corrado M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Klein Geltink RI; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Maccari ME; Center for Chronic Immunodeficiency, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Villa M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Carrizo GE; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Sanin DE; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Baixauli F; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Kelly B; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Curtis JD; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Haessler F; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Patterson A; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Field CS; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Caputa G; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Kyle RL; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Soballa M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Cha M; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Paul H; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Martin J; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Grzes KM; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Flachsmann L; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Mitterer M; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Zhao L; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Winkler F; Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Faculty of Biology, University of Freiburg, Freiburg, Germany., Rafei-Shamsabadi DA; Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Meiss F; Department of Dermatology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Bengsch B; Clinic for Internal Medicine II, Gastroenterology, Hepatology, Endocrinology, and Infectious Diseases, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany., Zeiser R; Signaling Research Centers BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.; Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Puleston DJ; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., O'Sullivan D; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany., Pearce EJ; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Faculty of Biology, University of Freiburg, Freiburg, Germany., Pearce EL; Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany. epearce6@jhmi.edu.; Bloomberg-Kimmel Institute for Cancer Immunotherapy and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. epearce6@jhmi.edu.

Publikováno v: Nature immunology [Nat Immunol] 2023 Mar; Vol. 24 (3), pp. 516-530. Date of Electronic Publication: 2023 Feb 02.

Proteomic Profiling of Fibroblasts Isolated from Chronic Wounds Identifies Disease-Relevant Signaling Pathways.

Autor: Berberich B; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Thriene K; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany; Institute for Prevention and Cancer Epidemiology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Gretzmeier C; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Kühl T; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Bayer H; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Athanasiou I; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Rafei-Shamsabadi DA; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Bruckner-Tuderman L; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Nyström A; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Kiritsi D; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany., Dengjel J; Department of Dermatology, Faculty of Medicine, Medical Center - University of Freiburg, Freiburg im Breisgau, Germany; Department of Biology, University of Fribourg, Fribourg, Switzerland. Electronic address: joern.dengjel@unifr.ch.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2020 Nov; Vol. 140 (11), pp. 2280-2290.e4. Date of Electronic Publication: 2020 Apr 17.

Lack of Type 2 Innate Lymphoid Cells Promotes a Type I-Driven Enhanced Immune Response in Contact Hypersensitivity.

Autor: Rafei-Shamsabadi DA; Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., van de Poel S; Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Dorn B; Experimental Dermatology and Allergy Research Group, Department of Dermatology and Allergology, University Medical Center Giessen and Marburg, Campus Giessen, Justus Liebig University, Giessen, Germany., Kunz S; Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Martin SF; Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Klose CSN; Institute of Medical Microbiology and Hygiene, University Medical Center, Freiburg, Germany., Arnold SJ; Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany., Tanriver Y; Institute of Medical Microbiology and Hygiene, University Medical Center, Freiburg, Germany., Ebert K; Institute of Medical Microbiology and Hygiene, University Medical Center, Freiburg, Germany., Diefenbach A; Department of Microbiology, Charité-University Medical Centre Berlin, Berlin, Germany., Halim TYF; Medical Research Council, Laboratory of Molecular Biology, Cambridge, Cambridgeshire, UK., McKenzie ANJ; Medical Research Council, Laboratory of Molecular Biology, Cambridge, Cambridgeshire, UK., Jakob T; Allergy Research Group, Department of Dermatology, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany; Experimental Dermatology and Allergy Research Group, Department of Dermatology and Allergology, University Medical Center Giessen and Marburg, Campus Giessen, Justus Liebig University, Giessen, Germany. Electronic address: thilo.jakob@derma.med.uni-giessen.de.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2018 Sep; Vol. 138 (9), pp. 1962-1972. Date of Electronic Publication: 2018 Mar 09.

Epidermal Barrier Dysfunction in Atopic Dermatitis.

Autor: Fernandes Gomes, Tiago¹ tiagofgomesd@gmail.com, Calado, Rebeca², Gonçalo, Margarida^2,3

Publikováno v: Revista da Sociedade Portuguesa de Dermatologia e Venereologia. 2021, Vol. 79 Issue 3, p207-216. 10p.